Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) Operating Income (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Operating Income for 7 consecutive years, with -$124.7 million as the latest value for Q4 2025.

  • Quarterly Operating Income fell 323.86% to -$124.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.2 million through Dec 2025, down 76.33% year-over-year, with the annual reading at $45.2 million for FY2025, 76.33% down from the prior year.
  • Operating Income hit -$124.7 million in Q4 2025 for Harmony Biosciences Holdings, down from $65.5 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $65.5 million in Q3 2025 to a low of -$124.7 million in Q4 2025.
  • Historically, Operating Income has averaged $31.8 million across 5 years, with a median of $40.3 million in 2023.
  • Biggest five-year swings in Operating Income: soared 442.05% in 2023 and later crashed 323.86% in 2025.
  • Year by year, Operating Income stood at $28.6 million in 2021, then skyrocketed by 66.3% to $47.6 million in 2022, then decreased by 15.58% to $40.2 million in 2023, then surged by 38.64% to $55.7 million in 2024, then plummeted by 323.86% to -$124.7 million in 2025.
  • Business Quant data shows Operating Income for HRMY at -$124.7 million in Q4 2025, $65.5 million in Q3 2025, and $48.2 million in Q2 2025.